Article
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.
Proceedings of the National Academy of Sciences of the United States of America - 16 May 2006
Ji Hongbin, Zhao Xiaojun, Yuza Yuki, Shimamura Takeshi, Li Danan, Protopopov Alexei, Jung Boonim L, McNamara Kate, Xia Huili, Glatt Karen A, Thomas Roman K, Sasaki Hidefumi, Horner James W, Eck Michael, Mitchell Albert, Sun Yangping, Al-Hashem Ruqayyah, Bronson Roderick T, Rabindran Sridhar K, Discafani Carolyn M, Maher Elizabeth, Shapiro Geoffrey I, Meyerson Matthew, Wong Kwok-Kin
Abstract excerpt
The tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva) have shown anti-tumor activity in the treatment of non-small cell lung cancer (NSCLC). Dramatic and durable responses have occurred in NSCLC tumors with mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). In contrast, these inhibitors have shown limited efficacy in glioblastoma, where a distinct EGFR...
Topics
- Animals
- Antineoplastic Agents
- Cell Line
- Cyclin-Dependent Kinase Inhibitor p16
- ErbB Receptors
- Erlotinib Hydrochloride
- Gefitinib
- Humans